This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Chart of the Day: Facebook Video

01/29/14 - 12:50 PM EST

While Alibaba may be more of a focus for Yahoo than the core business, there is no question that the underlying trends are not strong. Meanwhile, Google and Facebook remain favorites and are buyable for the long-term.


The Emerging Market Enigma: A bottoms up approach

01/27/14 - 06:12 PM EST

Emerging market question marks remain front & center. And while countries like Argentina and Turkey are dominating headlines, front & center is none other than China, with worries of slowing economic growth, with the factory sector contracting in January for the first time in six months. The emerging market question marks seem to be issue number one for the market right now, particularly as taper has been expected and is gradual.So, when thinking about China: When panic sets in, we turn to company-specific data. Ultimately, broader economic read concerns will dominate headlines, but let's turn back to some positive data we have gotten from individual companies, as there has been a good deal of positive news flow:


Markets Set to Open Higher, Caterpillar Tops Forecasts

01/27/14 - 09:27 AM EST

Take a quick look at my video, rounding up market movers this morning


Like Your Coffee Hot? Gems from Starbucks Conference Call

01/23/14 - 10:29 PM EST

The divergence between McDonald's and Starbuck's at these levels couldnt be greater


Opportunity Remains for Netflix

01/23/14 - 10:23 PM EST

When you look at Netflix's current price of $389, an all-time high for the company, and compare it with the high $40 price range back in 2009, there's no question that this one has been a clear winner.But that simple comparison ignores the many ups and downs the stock has taken... and it is the ups and downs that provide a good lesson for opportunities when it comes to momentum stocks...


2014: The Year of the Activist Investor?

01/22/14 - 10:00 PM EST

It's just a couple of weeks into 2014, and activism is already dominating headlines.We got word earlier this week that activist investor Nelson Peltz is joining the Mondelez board. Trian's Peltz had been pushing for a merger of Mondelez with Pepsi's snack business-- and while he will drop this push now having a position on the board, Peltz will still push for margin improvement and top-line growth. Next up, Third Point's Dan Loeb has taken a large stake in Dow Chemical with a push for the company to sell off its petrochemical business. Remember, we have seen strong value creation from Dupont and PPG Industries as they have become more specialty chemical companies. And then, Carl Icahn, who is also adding to his Apple stake, submitted a proposal to Ebay to spin off its PayPal business and nominated two of his employees as candidates for the board. Or how about Elliott management coming after Riverbed Technology and Juniper Networks...


Don't Read Too Much Into the Downers of the Dow

01/21/14 - 10:34 PM EST

Today's market ended with the Dow Jones Industrial Average down 44 points while the S&P was in fact up 0.28%. Why the divergence? Key Dow components reported quarters that were seen as disappointing, but ultimately, as I highlight below, these names are still well positioned and we still see an underlying healthy market.


J.P. Morgan Confab Focus Reminds Us Upside Remains In Biotech

01/17/14 - 03:30 PM EST

Biotechnology stocks have been front and center this week amidst the J.P. Morgan Healthcare conference, the big conference held in San Francisco each January where so many companies reveal important outlooks for the year and important pipeline updates. Historically, biotechnology stocks have outperformed during this conference week -- and we have seen broad-based strength from the group -- but more importantly, investors are provided with a reiteration of some of the strong themes that will dominate 2014...


Buy Best Names of Shale Revolution on Pullbacks: Best Acreage and Company-Specific Catalysts

01/16/14 - 07:27 PM EST

2013 was the year of the Permian Basin, 2012 was the year of the Eagle Ford, and 2011 was the year of the Bakken. What is the theme for 2014? At this point, most of the plays have been discovered, with even new finds in the Utica "known." So key is choosing the names with the BEST acreage -- because they will continue to outperform....


Another Side of the Security Play: LifeLock

01/16/14 - 03:55 PM EST

Another side of the security play: Keep an eye out for LifeLock's interview on Mad Money Tonight


Nicole Urken is Research Director of Mad Money and Jim Cramer's researcher at TheStreet. Nicole analyzes stocks and develops a strategic macro outlook, which she incorporates into segment ideas for CNBC's "Mad Money." Nicole also supports Jim's other endeavors including "Squawk on the Street,", and his latest best-selling book "Get Rich Carefully."

Previously, she worked as an investment banking analyst for the Industrials Group in Goldman Sachs' New York office. Born and raised in Princeton, New Jersey, Nicole graduated with honors from Harvard College, where she served as executive editor of The Harvard Crimson.


DOW 16,614.81 +215.14 1.31%
S&P 500 1,941.28 +37.27 1.96%
NASDAQ 4,419.4780 +103.4040 2.40%

Nicole's Tweets

Brokerage Partners

Select the service that is right for you!

Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs